Lung Cancer | Topics

 
Monitoring Response to Therapy in NSCLC
October 18, 2021

Roy S. Herbst, MD, PhD, reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.

Treatment Options in Non–Small Cell Lung Cancer
October 18, 2021

Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.

Key Takeaways From the eNRGy1 Global Multicenter Registry Study
October 15, 2021

Experts Alexander Spira, MD, PhD, FACP, and D. Ross Camidge, MD, PhD, share insight and key takeaways from the eNRGy1 global registry study.

Edward B. Garon, MD, Discusses Outcomes in NSCLC With Dato-DXd From TROPION-PanTumor01
October 14, 2021

CancerNetwork® sat down with Edward B. Garon, MD, at the 2021 World Conference on Lung Cancer to talk about key findings with datopotamab deruxtecan therapy in patients with non–small cell lung cancer and other ongoing trials.

NRG1 Fusion–Driven Lung Cancers: Clinicopathologic Features and Response to Therapy
October 08, 2021

A review of data from the eNRGy1 global registry study, with deference to the efficacy of current therapies and clinicopathologic features.

Alexander Spira, MD, PhD, FACP, Discusses Impacts of COVID-19 at Individual Treatment Facilities
September 25, 2021

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about COVID-19 and immediate changes that took place during the pandemic.

Nivolumab Plus Ipilimumab Demonstrate Continued Survival Benefit in All Subgroups in Unresectable Malignant Pleural Mesothelioma
September 18, 2021

Findings from the phase 3 CheckMate 743 trial indicated that patients with unresectable malignant pleural mesothelioma derived a continued overall survival benefit after being treated with nivolumab and ipilimumab.

Mobocertinib Plus T-DM1 Combo Shows Efficacy in HER2 Exon 20 Insertion–Mutant Lung Cancer Cell Lines
September 13, 2021

With the combination of mobocertinib and T-DM1, potent preclinical efficacy was observed in lung cancer cells with HER2 exon 20 insertion mutations.

Alexander Spira, MD, PhD, FACP, Discusses Biomarker-Guided Treatment in Lung Cancer at 2021 WCLC
September 10, 2021

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about KRAS as a therapy biomarker in lung cancer.

Study Confirms Heightened Hospitalizations, Mortality With COVID-19 in Patients With Malignant Pleural Mesothelioma
September 09, 2021

In the early days of the COVID-19 pandemic, patients with malignant pleural mesothelioma were more likely to be hospitalized or die from COVID-19 versus the overall population.